HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Results of weighted arcsine-transformed linear regression of the age-and sex-standardised epilepsy prevalence (y) and age- and sex-standardised anti-Ov16 seroprevalence (x<sub>1</s... by Luís-Jorge Amaral (16406704)

Subjects:

Comparison of (a) Chao index and (b) Shannon diversity index of the fecal microbiota in WT and Lep KO mice. by Yu Sang Choi (22656230)

Aβ and vGlut2 staining of 6-, 9-, and 12-month dLGN sections show significant plaque load and accelerated loss of retinal ganglion cell axon terminals in the 5xFAD mice. by Shaylah McCool (20818280)

National age-standardized rates of DALYs and ASDR of IHD attributable to HSBP and their estimated annual percentage changes in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Age-specific burden of IHD attributable to HSBP for males and females in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Global burden of IHD attributable to HSBP from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

Age-specific estimated annual percentage changes in DALYs and death rates for 21 regions from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

SDI-based age-standardized rates of DALYs and ASDR for IHD attributable to HSBP. by Zhenhua Zhuang (11192745)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant reduction in colony-forming ability was observed in U87MG cells treated with 100ΜM SHG-44 compared to 100ΜM cis-platin and the untreated control. …”

Modeling the relationship between cancer level in hemolymph and MarBTN in tank eDNA. by Rachael M. Giersch (22331947)

Supplementary Tables 1–8. by Juliane F. Tampé (19976538)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects: